Thus co-targeting the mTOR signaling circuitry based on the genetic stratification of PI3K/mTOR network subtypes with IO agents, may represent a novel precision immune therapeutic approach for HNSCC. This evidence concerns the gene PIK3CA and head and neck squamous cell carcinoma.